Deflegmin Sirup 30 mg/5ml 120 ml

Deflegmin 30 mg/5 ml syrup 120 ml

Name: Deflegmin
Form: syrup
Dose: 0.03 g/5ml
Package : 120 ml

Deflegmin Description and indications

The drug is used supportively in acute and chronic diseases of the respiratory system, proceeding with abnormal secretion and difficult expectoration of bronchial secretions in acute or chronic bronchitis or pneumonia, asthma in bronchial dilatation, cystic fibrosis, inflammation of the larynx, nose, throat and sinuses

Action

The syrup contains ambroxol as an active substance, which has an expectorant and mucolytic effect - it dilutes viscous secretions that cause coughing and facilitates their removal from the bronchi. It alleviates coughing.

Ambroxol is a metabolite of bromohexine, which exhibits mucolytic activity. It increases the secretion of mucus in the respiratory tract, stimulates the production of pulmonary surfactant and the function of respiratory epithelial cilia. As a result, it increases the amount of mucus in the airways and improves its transport (mucociliary clearance). By increasing fluid secretion into the bronchial tree and improving mucociliary clearance, it facilitates expectoration and relieves coughing.

Composition - what ingredients the drug Deflegmin contains

5 ml of syrup contains 30 mg of ambroxol hydrochloride.

Excipients: sorbitol, glycerol, propylene glycol, sodium benzoate, purified water, masking aroma, hydrochloric acid 10%.

Dosage - how to use the drug Deflegmin

Adults and children over 12 years of age: 5 ml of syrup 30 mg/5 ml 3 times a day for 2-3 days, and then 5 ml of syrup 30 mg/5 ml 2 times a day.

Contraindications

Hypersensitivity to the active substance or to any of the excipients.

Notes and warnings about the drug Deflegmin

This is a medication. For safety, use it according to the package insert. Do not exceed the maximum dose of the drug. If in doubt, consult your doctor or pharmacist.

Special warnings / Precautions

Use with caution in patients with gastric or duodenal ulcer disease and renal or hepatic insufficiency. The preparation should be used with caution in patients with impaired cough reflex or impaired bronchial ciliary clearance due to the possibility of retention of secretions in the airways. In patients with bronchial asthma, ambroxol may aggravate cough at the beginning of treatment. The preparation should not be used immediately before bedtime. The medicinal product 30 mg tabl. contains lactose. It should not be used in patients with rare hereditary intolerance of galactose, Lapp lactase deficiency or glucose-galactose malabsorption syndrome. The preparation does not affect the ability to drive or operate machinery.

Interactions

Concomitant use of ambroxol with antibiotics (amoxicillin, cefuroxime, erythromycin, doxycycline) increases the concentration of antibiotics in the lung parenchyma. Ambroxol should not be used concomitantly with antitussives (e.g. codeine), as they may inhibit the cough reflex and impede expectoration of liquefied mucus from the bronchial tree. No clinically significant adverse interactions of ambroxol with other drugs have been demonstrated.

Pregnancy and lactation

Ambroxol hydrochloride crosses the placental barrier. Animal studies have shown no direct or indirect adverse effects on pregnancy, embryonic and/or fetal development, the course of labor or postnatal development. Based on extensive clinical experience in pregnant women after the 28th week of pregnancy, no harmful effects of ambroxol on the fetus have been demonstrated. Nevertheless, the usual precautions should be taken when using the drug product during pregnancy. Especially in the first trimester of pregnancy, the use of the product is not recommended. Ambroxol hydrochloride passes into breast milk. Although adverse effects on a breastfed child are not expected, the product is not recommended for use in breastfeeding women.

Adverse effects

Immune system disorders (unknown): Anaphylactic reactions, including anaphylactic shock, angioedema,pruritus and other hypersensitivity reactions. Gastrointestinal disorders (common): nausea; (uncommon): vomiting, diarrhea, indigestion and abdominal pain. Skin and subcutaneous tissue disorders (rare): rash, urticaria; (very rare): severe skin reactions, such as Stevens-Johnson syndrome, toxic epidermal necrolysis, having a temporary association with the use of mucolytic drugs.

Overdose

No specific symptoms of ambroxol overdose in humans have been described to date. Symptoms reported after accidental overdose and/or misuse of ambroxol corresponded to adverse reactions occurring after administration of the product at recommended doses. Symptomatic treatment may be required.

Responsible Entity
Bausch Health